Role of the prorenin receptor in endometrial cancer cell growth.

Martin, JH; Mohammed, R; Delforce, SJ; Skerrett-Byrne, DA; de Meaultsart, CC; Almazi, JG; Stephens, AN; Verrills, NM; Dimitriadis, E; Wang, Y; Lumbers, ER; Pringle, KG

Role of the prorenin receptor in endometrial cancer cell growth.

Martin, JH Mohammed, R Delforce, SJ Skerrett-Byrne, DA de Meaultsart, CC Almazi, JG Stephens, AN Verrills, NM Dimitriadis, E Wang, Y Lumbers, ER Pringle, KG

Permalink

Publisher:: Impact Journals, LLC
Publication Type:: Journal Article
Citation:: Oncotarget, 2022, 13, (1), pp. 587-599
Issue Date:: 2022

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Download Published versionAdobe PDF (4.29 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Martin, JH
dc.contributor.author	Mohammed, R
dc.contributor.author	Delforce, SJ
dc.contributor.author	Skerrett-Byrne, DA
dc.contributor.author	de Meaultsart, CC
dc.contributor.author	Almazi, JG
dc.contributor.author	Stephens, AN
dc.contributor.author	Verrills, NM
dc.contributor.author	Dimitriadis, E
dc.contributor.author	Wang, Y
dc.contributor.author	Lumbers, ER
dc.contributor.author	Pringle, KG
dc.date.accessioned	2023-07-09T00:46:28Z
dc.date.available	2022-03-14
dc.date.available	2023-07-09T00:46:28Z
dc.date.issued	2022
dc.identifier.citation	Oncotarget, 2022, 13, (1), pp. 587-599
dc.identifier.issn	1949-2553
dc.identifier.issn	1949-2553
dc.identifier.uri	http://hdl.handle.net/10453/171354
dc.description.abstract	Endometrial cancer is the most diagnosed gynecological malignancy. Despite numerous scientific advances, the incidence and mortality rate of endometrial cancer continues to rise. Emerging evidence suggests a putative role of the (pro)renin receptor ((P)RR), in the ontogenesis of endometrial cancer. The (P)RR is implicated in breast cancer and pancreatic carcinoma pathophysiology by virtue of its role in proliferation, angiogenesis, fibrosis, migration and invasion. Thus, we aimed to investigate the functional role of the (P)RR in human endometrial cancer. We employed an siRNA-mediated knockdown approach to abrogate (P)RR expression in the endometrial epithelial cell lines; Ishikawa, AN3CA and HEC-1-A and examined cellular proliferation and viability. We also carried out a sophisticated proteomic screen to explore potential pathways via which the (P)RR is acting in endometrial cancer physiology. These data confirmed that the (P)RR is critical for endometrial cancer development, contributing to both its proliferative capacity and in the maintenance of cell viability. This is likely mediated through proteins such as MGA, SLC4A7, SLC7A11 or DHRS2, which were reduced following (P)RR knockdown. These putative protein interactions/pathways, which rely on the presence of the (P)RR, are likely to contribute to endometrial cancer progression and could therefore, represent several novel therapeutic targets for endometrial cancer.
dc.format	Electronic-eCollection
dc.language	eng
dc.publisher	Impact Journals, LLC
dc.relation.ispartof	Oncotarget
dc.relation.isbasedon	10.18632/oncotarget.28224
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1112 Oncology and Carcinogenesis
dc.subject.classification	3211 Oncology and carcinogenesis
dc.subject.mesh	Cell Line, Tumor
dc.subject.mesh	Cell Proliferation
dc.subject.mesh	Cell Transformation, Neoplastic
dc.subject.mesh	Endometrial Neoplasms
dc.subject.mesh	Female
dc.subject.mesh	Humans
dc.subject.mesh	Proteomics
dc.subject.mesh	RNA, Small Interfering
dc.subject.mesh	Receptors, Cell Surface
dc.subject.mesh	Renin
dc.subject.mesh	Prorenin Receptor
dc.subject.mesh	Cell Line, Tumor
dc.subject.mesh	Humans
dc.subject.mesh	Endometrial Neoplasms
dc.subject.mesh	Cell Transformation, Neoplastic
dc.subject.mesh	Renin
dc.subject.mesh	Receptors, Cell Surface
dc.subject.mesh	RNA, Small Interfering
dc.subject.mesh	Proteomics
dc.subject.mesh	Cell Proliferation
dc.subject.mesh	Female
dc.subject.mesh	Prorenin Receptor
dc.subject.mesh	Cell Line, Tumor
dc.subject.mesh	Cell Proliferation
dc.subject.mesh	Cell Transformation, Neoplastic
dc.subject.mesh	Endometrial Neoplasms
dc.subject.mesh	Female
dc.subject.mesh	Humans
dc.subject.mesh	Proteomics
dc.subject.mesh	RNA, Small Interfering
dc.subject.mesh	Receptors, Cell Surface
dc.subject.mesh	Renin
dc.subject.mesh	Prorenin Receptor
dc.title	Role of the prorenin receptor in endometrial cancer cell growth.
dc.type	Journal Article
utslib.citation.volume	13
utslib.location.activity	United States
utslib.for	1112 Oncology and Carcinogenesis
utslib.copyright.status	open_access	*
dc.date.updated	2023-07-09T00:46:22Z
pubs.issue	1
pubs.publication-status	Published online
pubs.volume	13
utslib.citation.issue	1

Abstract:

Endometrial cancer is the most diagnosed gynecological malignancy. Despite numerous scientific advances, the incidence and mortality rate of endometrial cancer continues to rise. Emerging evidence suggests a putative role of the (pro)renin receptor ((P)RR), in the ontogenesis of endometrial cancer. The (P)RR is implicated in breast cancer and pancreatic carcinoma pathophysiology by virtue of its role in proliferation, angiogenesis, fibrosis, migration and invasion. Thus, we aimed to investigate the functional role of the (P)RR in human endometrial cancer. We employed an siRNA-mediated knockdown approach to abrogate (P)RR expression in the endometrial epithelial cell lines; Ishikawa, AN3CA and HEC-1-A and examined cellular proliferation and viability. We also carried out a sophisticated proteomic screen to explore potential pathways via which the (P)RR is acting in endometrial cancer physiology. These data confirmed that the (P)RR is critical for endometrial cancer development, contributing to both its proliferative capacity and in the maintenance of cell viability. This is likely mediated through proteins such as MGA, SLC4A7, SLC7A11 or DHRS2, which were reduced following (P)RR knockdown. These putative protein interactions/pathways, which rely on the presence of the (P)RR, are likely to contribute to endometrial cancer progression and could therefore, represent several novel therapeutic targets for endometrial cancer.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/171354